PMID- 17489730 OWN - NLM STAT- MEDLINE DCOM- 20090119 LR - 20070510 IS - 1744-8352 (Electronic) IS - 1473-7159 (Linking) VI - 7 IP - 3 DP - 2007 May TI - PNA FISH: present and future impact on patient management. PG - 231-6 AB - Inappropriate and inaccurate antimicrobial therapy can lead to adverse patient outcomes and also the development of antimicrobial resistance. Peptide nucleic acid (PNA) fluorescence in situ hybridization (FISH) gives rapid reporting with highly sensitive and specific results to clinicians within 3 h after blood cultures turn positive, thereby offering targeted therapeutics where necessary. It is simple to establish compared with real-time PCR and has resulted in significant cost savings for hospitals. PNA FISH is a promising future technology for the microbiology laboratory that will impact on patient management and clinical guidelines. This article will review the clinical data supporting these new technologies. FAU - Forrest, Graeme N AU - Forrest GN AD - University of Maryland, Division of Infectious Diseases, Baltimore, MD 21201, USA. gforrest@medicine.umaryland.edu LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Review PL - England TA - Expert Rev Mol Diagn JT - Expert review of molecular diagnostics JID - 101120777 RN - 0 (Peptide Nucleic Acids) SB - IM MH - Bacterial Infections/*diagnosis/economics/*therapy MH - Candidiasis/*diagnosis/economics/*therapy MH - *Forecasting MH - Humans MH - In Situ Hybridization, Fluorescence/economics/methods/*trends MH - *Peptide Nucleic Acids MH - Reproducibility of Results MH - Reverse Transcriptase Polymerase Chain Reaction/trends RF - 44 EDAT- 2007/05/11 09:00 MHDA- 2009/01/20 09:00 CRDT- 2007/05/11 09:00 PHST- 2007/05/11 09:00 [pubmed] PHST- 2009/01/20 09:00 [medline] PHST- 2007/05/11 09:00 [entrez] AID - 10.1586/14737159.7.3.231 [doi] PST - ppublish SO - Expert Rev Mol Diagn. 2007 May;7(3):231-6. doi: 10.1586/14737159.7.3.231.